Also trades as: CING (NASDAQ) · $vol 2M
CINGW NASDAQ
Cingulate Inc.
1W: -24.2%
1M: -44.0%
3M: -81.0%
YTD: -91.5%
1Y: -89.8%
3Y: -97.7%
$0.01
+0.00 (+0.00%)
Weekly Expected Move ±54.3%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.0M
52W Range0.0026-0.12
Volume100
Avg Volume19,571
Beta-0.91
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOShane J. Schaffer
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2021-12-08
Websitecingulate.com
1901 West 47th Place
Kansas City, KS 66205
US
Kansas City, KS 66205
US
913 942 2300
About Cingulate Inc.
Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions. Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders. Established in 2012, Cingulate Inc. maintains its main office in Kansas City, Kansas, and also operates a facility in Morristown, New Jersey.
Latest News
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Cingulate Receives Complete Response Letter from FDA for CTx-1301
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Cingulate Inc. (NASDAQ:CINGW) Sees Large Increase in Short Interest
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Silva Raul R. | A-Award | 4,526 | — | 2026-03-09 |
| Silva Raul R. | F-InKind | 1,828 | — | 2026-03-09 |
| Schaffer Shane J. | A-Award | 6,862 | — | 2026-03-09 |
| Schaffer Shane J. | F-InKind | 2,959 | — | 2026-03-09 |
| Callahan Jennifer L. | A-Award | 15,329 | — | 2026-03-09 |